DE102011121069A1 - Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene - Google Patents

Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene Download PDF

Info

Publication number
DE102011121069A1
DE102011121069A1 DE102011121069A DE102011121069A DE102011121069A1 DE 102011121069 A1 DE102011121069 A1 DE 102011121069A1 DE 102011121069 A DE102011121069 A DE 102011121069A DE 102011121069 A DE102011121069 A DE 102011121069A DE 102011121069 A1 DE102011121069 A1 DE 102011121069A1
Authority
DE
Germany
Prior art keywords
recombinant yeast
protein
foreign
yeast according
ibdv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE102011121069A
Other languages
German (de)
English (en)
Inventor
Karin Breunig
Sven-Erik Behrens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martin Luther University Halle-Wittenberg
Original Assignee
Martin Luther University Halle-Wittenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47681476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE102011121069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martin Luther University Halle-Wittenberg filed Critical Martin Luther University Halle-Wittenberg
Priority to DE102011121069A priority Critical patent/DE102011121069A1/de
Priority to MX2014007183A priority patent/MX368484B/es
Priority to BR112014014390-0A priority patent/BR112014014390B1/pt
Priority to ES12823073.7T priority patent/ES2690792T3/es
Priority to CA2859231A priority patent/CA2859231C/en
Priority to DK12823073.7T priority patent/DK2844759T3/en
Priority to JP2014546315A priority patent/JP6313215B2/ja
Priority to EP12823073.7A priority patent/EP2844759B1/de
Priority to KR1020147019123A priority patent/KR102027400B1/ko
Priority to PCT/DE2012/001205 priority patent/WO2013107436A1/de
Priority to DE112012005213.7T priority patent/DE112012005213A5/de
Priority to PL12823073T priority patent/PL2844759T3/pl
Priority to CN201280062015.XA priority patent/CN104428417B/zh
Priority to US14/364,238 priority patent/US11065312B2/en
Priority to RU2014127435A priority patent/RU2630620C2/ru
Publication of DE102011121069A1 publication Critical patent/DE102011121069A1/de
Priority to ZA2014/05034A priority patent/ZA201405034B/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
DE102011121069A 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene Ceased DE102011121069A1 (de)

Priority Applications (16)

Application Number Priority Date Filing Date Title
DE102011121069A DE102011121069A1 (de) 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
RU2014127435A RU2630620C2 (ru) 2011-12-13 2012-12-12 Вакцинация с помощью рекомбинантных дрожжей с формированием защитного гуморального иммунного ответа против определенных антигенов
KR1020147019123A KR102027400B1 (ko) 2011-12-13 2012-12-12 정의된 항원에 대한 보호 체액성 면역 반응을 형성하는 재조합 효모를 이용한 예방 접종
DE112012005213.7T DE112012005213A5 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
ES12823073.7T ES2690792T3 (es) 2011-12-13 2012-12-12 Vacunación por medio de levadura recombinante mediante generación de una respuesta inmunitaria humoral protectora contra antígenos definidos
CA2859231A CA2859231C (en) 2011-12-13 2012-12-12 Vaccination by means of recombinant yeast by creation of a protective humoral immune response against defined antigens
DK12823073.7T DK2844759T3 (en) 2011-12-13 2012-12-12 Vaccination by recombinant yeast by eliciting a protective humoral immune response against defined antigens
JP2014546315A JP6313215B2 (ja) 2011-12-13 2012-12-12 組み換え酵母を用いた、定義された抗原に対する防御的体液性免疫応答の生成による予防接種
EP12823073.7A EP2844759B1 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene
MX2014007183A MX368484B (es) 2011-12-13 2012-12-12 Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.
PCT/DE2012/001205 WO2013107436A1 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene
BR112014014390-0A BR112014014390B1 (pt) 2011-12-13 2012-12-12 Levedura recombinante, seus usos, método para produção de uma composição de vacina subcutânea, oligonucleotídeo, e vetor de expressão
PL12823073T PL2844759T3 (pl) 2011-12-13 2012-12-12 Szczepienie z zastosowaniem rekombinowanych drożdży poprzez wywołanie ochronnej humoralnej odpowiedzi odpornościowej przeciwko określonym antygenom
CN201280062015.XA CN104428417B (zh) 2011-12-13 2012-12-12 利用针对确定抗原产生保护性体液免疫应答的重组酵母进行的接种
US14/364,238 US11065312B2 (en) 2011-12-13 2012-12-12 Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens
ZA2014/05034A ZA201405034B (en) 2011-12-13 2014-07-10 Vaccination by means of recombinant yeast by producing a protective humoral immune response against defined antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011121069A DE102011121069A1 (de) 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene

Publications (1)

Publication Number Publication Date
DE102011121069A1 true DE102011121069A1 (de) 2013-06-13

Family

ID=47681476

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102011121069A Ceased DE102011121069A1 (de) 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
DE112012005213.7T Withdrawn DE112012005213A5 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE112012005213.7T Withdrawn DE112012005213A5 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene

Country Status (15)

Country Link
US (1) US11065312B2 (enExample)
EP (1) EP2844759B1 (enExample)
JP (1) JP6313215B2 (enExample)
KR (1) KR102027400B1 (enExample)
CN (1) CN104428417B (enExample)
BR (1) BR112014014390B1 (enExample)
CA (1) CA2859231C (enExample)
DE (2) DE102011121069A1 (enExample)
DK (1) DK2844759T3 (enExample)
ES (1) ES2690792T3 (enExample)
MX (1) MX368484B (enExample)
PL (1) PL2844759T3 (enExample)
RU (1) RU2630620C2 (enExample)
WO (1) WO2013107436A1 (enExample)
ZA (1) ZA201405034B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114870006A (zh) * 2022-04-13 2022-08-09 河北农业大学 一种etec疫苗及其应用
WO2026119376A1 (de) 2024-12-03 2026-06-11 Verovaccines Gmbh Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
JP7372647B2 (ja) * 2019-06-27 2023-11-01 国立研究開発法人農業・食品産業技術総合研究機構 α‐リノレン酸産生能が向上した酵母またはその培養物
CN110646614B (zh) * 2019-07-15 2023-05-23 新乡学院 Ibdv抗体的elisa试剂盒和测试方法、有效抗体效价确定方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
WO2001054649A2 (en) 2000-01-28 2001-08-02 Michael Christy Variable-force monofilament sensory device
WO2006044923A2 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
US20070166323A1 (en) 2000-11-15 2007-07-19 Regents Of The University Of Colorado Yeast-dendritic cell vaccines and uses thereof
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
DE102008057451A1 (de) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643216B2 (en) * 1989-05-30 1993-11-11 Commonwealth Scientific And Industrial Research Organisation Production of IBDV VP2 in highly immunogenic form
KR101085310B1 (ko) * 2003-03-24 2011-11-22 인터벳 인터내셔널 비.브이. 감염성 점액낭병 바이러스 돌연변이체 및 백신
ES2242542B1 (es) * 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
WO2006078318A2 (en) * 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2008153339A2 (en) * 2007-06-12 2008-12-18 Univ Sungkyunkwan Found A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system
CN101638824B (zh) 2009-03-16 2012-08-08 浙江双友物流器械股份有限公司 一种耐磨织带

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
WO2001054649A2 (en) 2000-01-28 2001-08-02 Michael Christy Variable-force monofilament sensory device
US20070166323A1 (en) 2000-11-15 2007-07-19 Regents Of The University Of Colorado Yeast-dendritic cell vaccines and uses thereof
US20090304741A1 (en) 2000-11-15 2009-12-10 Globelmmune, Inc. Yeast-Dendritic Cell Vaccines and Uses Thereof
WO2006044923A2 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
DE102008057451A1 (de) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
WO2010054649A2 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
Backhaus et al., 2011
Backhaus, K. et al. Milk and sugar: Regulation of cell wall synthesis in the milk yeast Kluyveromyces lactis. European Journal of Cell Biology 90, 745-750 (2011)
Bathurst, 1994
Bathurst, I. C. Protein Expression in Yeast as an Approach to Production of Recombinant Malaria Antigens. The American Journal of Tropical Medicine and Hygiene 50, 20-26 (1994)
Botstein D, Falco, S. C., Stewart, S. E., Brennan, M., Scherer, S., Stinchcomb, D. T., Struhl, K. & Davis, R. W. Sterile host yeast (SHY): a eukaryotic system of biological containment for recombinant DNA experiments. Gene 8, 17-24 (1979)
Botstein et al., 1979
Breunig et al. Regulation of primary carbon metabolism in Kluyveromyces lactis. Enzyme Microbial Technology 26, 771-780 (2000)
Breunig et al., 2000
Chen and Clark-Walker, 1995
Chen et al., 1995
Chen, X. J. & Clark-Walker, G. D. Specific mutations in alpha- and gamma-subunits of F1-ATPase affect mitochondrial genome integrity in the petite-negative yeast Kluyveromyces lactis. EMBO Journal 14, 3277-3286 (1995)
Clark-Walker, 2007
Clark-Walker, G. D. The F1-ATPase inhibitor Inh1 (IF1) affects suppression of mtDNA loss-lethality in Kluyveromyces lactis. FEMS Yeast Research 7, 665-674 (2007)
Donnini et al., 2004
Donnini, C. et al. Improved Production of Heterologous Proteins by a Glucose Repression-Defective Mutant of Kluyveromyces lactis. Applied and Environmental Microbiology 70, 2632-2638 (2004)
Engler-Blum et al., 1993
Engler-Blum, G., Meier, M., Frank, J. & Muller, G. A. Reduction of background problems in nonradioactive northern and southern blot analyses enables higher sensitivity than 32P-based hybridizations. Analytical Biochemistry 210, 235-244 (1993)
Gellissen & Hollenberg, 1997
Gellissen G. & Hollenberg C. P. Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis - a review. Gene 190, 87-97 (1997)
Granzow et al., 1997
Granzow, H. et al. A second form of infectious bursal disease virus-associated tubule contains VP4. Journal of Virology 71, 8879-8885 (1997)
Icard et al., 2008
Icard, A. H., Sellers, H. S., & Mundt, E. Detection of infectious bursal disease virus isolates with unknown antigenic properties by reverse genetics. Avian Disease 52, 590-598. (2008)
Jagadish et al. (1991)
Jagadish, M. N., Laughton, D. L., Azad, A. A. & Macreadie, I. G. Stable synthesis of viral protein 2 of infectious bursal disease virus in Saccharomyces cerevisiae. Gene 108, 275-279 (1991)
Kuger et al. (1990)
Kuger et al., 1990
Kuger, P., Gödecke, A. & Breunig, K. D. A mutation in the Zn-finger of the GAL4 homolog LAC9 results in glucose repression of its target genes. Nucleic Acids Research 18, 745-751 (1990)
Lu et al., 2004
Lu, Y. et al. Mutation-Selective Tumor Remission with Ras-Targeted, Whole Yeast-Based Immunotherapy. Cancer Research 64, 5084-5088 (2004)
Raab et al., 2010
Raab, D., Graf, M., Notka, F., Schödl, T. & Wagner, R. The Gene Optimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Systems and Synthetic Biology 4, 215-225 (2010)
Raschke and Ballou, 1972
Raschke und Ballou, 1972
Raschke, W. C. & Ballou, C. E. Characterization of a yeast mannan containing N-acetyl-D-glucosamine as an immunochemical determinant. Biochemistry 11, 3807-3816 (1972)
Saugar et al., 2005
Saugar, I. et al. Structural polymorphism of the major capsid protein of a double-stranded RNA virus: An Amphipathic [alpha] Helix as a Molecular Switch. Structure 13, 1007-1017 (2005)
Schröder et al., 2000
Schröder, A., van Loon, A. A. W. M., Goovaerts, D. & Mundt, E. Chimeras in noncoding regions between serotypes I and II of segment A of infectious bursal disease virus are viable and show pathogenic phenotype in chickens. Journal of General Virology 81, 533-540 (2000)
Stubbs and Wilson (2002) Curr. Opin. Mol. Ther. 4: 35-40
Stubbs et al., (2001) Nat. Med. 7: 625-629
Stubbs et al., 2001
Stubbs, A. C. & Wilson, C. C. Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses. Current Opinion of Molecular Therapy 4, 35-40 (2002)
Stubbs, A. C. et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nature Medicine 7, 625-629 (2001)
Uccelletti et al., 2004
Uccelletti, D., Farina, F., Mancini, P. & Palleschi, C. KlPMR1 inactivation and calcium addition enhance secretion of non-hyperglycosylated heterologous proteins in Kluyveromyces lactis. Journal of Biotechnology 109, 93-101 (2004)
van Ooyen et al. 2006
van Ooyen et al., 2006
Van Ooyen, A. J. Dekker, P., Huang, M., Olsthoorn, M. M., Jacobs, D. I., Colussi, P. A. & Taron, C. H. Heterologous protein production in the yeast Kluyveromyces lactis. FEMS Yeast Research 6, 381-392 (2006)
Wansley E. K. et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clinical Cancer Research 14, 4316-4325 (2008)
Wansley et al., (2008) Clin. Cancer Res. 14: 4316-4325
Zenke et al. 1993
Zenke, F. T., Zachariae, W., Lunkes, A., & Breunig, K. D. Gal80 proteins of Kluyveromyces lactis and Saccharomyces cerevisiae are highly conserved but contribute differently to glucose repression of the galactose regulon. Molecular and Cellular Biology 13, 7566-7576 (1993)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114870006A (zh) * 2022-04-13 2022-08-09 河北农业大学 一种etec疫苗及其应用
WO2026119376A1 (de) 2024-12-03 2026-06-11 Verovaccines Gmbh Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine
WO2026119879A1 (de) 2024-12-03 2026-06-11 Verovaccines Gmbh Sedimentations-stabilisierte formulierungen für hefe—basierte vakzine

Also Published As

Publication number Publication date
CN104428417A (zh) 2015-03-18
JP2015507472A (ja) 2015-03-12
PL2844759T3 (pl) 2019-01-31
MX2014007183A (es) 2014-11-25
EP2844759B1 (de) 2018-07-18
DE112012005213A5 (de) 2014-11-13
US11065312B2 (en) 2021-07-20
DK2844759T3 (en) 2018-11-05
RU2630620C2 (ru) 2017-09-11
CN104428417B (zh) 2020-05-05
ZA201405034B (en) 2015-12-23
MX368484B (es) 2019-10-04
WO2013107436A8 (de) 2015-01-15
BR112014014390A2 (pt) 2020-12-08
KR102027400B1 (ko) 2019-10-04
ES2690792T3 (es) 2018-11-22
KR20140105821A (ko) 2014-09-02
EP2844759A1 (de) 2015-03-11
RU2014127435A (ru) 2016-02-10
CA2859231A1 (en) 2013-07-25
US20150190486A1 (en) 2015-07-09
WO2013107436A1 (de) 2013-07-25
CA2859231C (en) 2019-04-30
JP6313215B2 (ja) 2018-04-18
BR112014014390B1 (pt) 2022-08-09

Similar Documents

Publication Publication Date Title
US5830702A (en) Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
Arnold et al. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit
EP2844759B1 (de) Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene
RS61261B1 (sr) Rekombinantni koi herpesvirus (khv) i vakcina za prevenciju bolesti prouzrokovane khv
JP2023166412A (ja) 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム
CN119331732A (zh) 一种基因缺失的重组弓形虫虫株疫苗及其构建方法
EP2403947B1 (de) Verfahren zur oralen/mukosalen vakzinierung mittels rekombinanter hefen
US20250352594A1 (en) Yeast Platform for the Production of Vaccines
EP1023453B1 (de) Tgc-verfahren zur induktion einer zielgerichteten, somatischen transgenität
EP4720275A2 (en) Vaccine for cats to block toxoplasma oocyst shedding and transmission
NL2030423B1 (en) Replication-deficient strain of canine distemper virus and construction method thereof
CN120624205A (zh) 重组弓形虫虫株、构建方法及其应用
KR101560793B1 (ko) 비병원성 전염성낭병 변이 바이러스 및 이의 백신으로써의 용도
CN116497049A (zh) 一种表达犬疱疹病毒gD糖基化蛋白的重组菌及其应用
EP1167529A2 (de) Vektorsystem zum Einbringen von DNA in eukaryonte Zellen

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R002 Refusal decision in examination/registration proceedings
R003 Refusal decision now final

Effective date: 20140214